These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32168026)

  • 1. The antinociceptive effects of a dual kappa-delta opioid receptor agonist in the mouse formalin test.
    Ulker E; Toma W; White A; Uprety R; Majumdar S; Damaj MI
    Behav Pharmacol; 2020 Apr; 31(2&3):174-178. PubMed ID: 32168026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MP1104, a mixed kappa-delta opioid receptor agonist has anti-cocaine properties with reduced side-effects in rats.
    Atigari DV; Uprety R; Pasternak GW; Majumdar S; Kivell BM
    Neuropharmacology; 2019 May; 150():217-228. PubMed ID: 30768946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mixed kappa and delta opioid receptor agonist, MP1104, attenuates chemotherapy-induced neuropathic pain.
    Atigari DV; Paton KF; Uprety R; Váradi A; Alder AF; Scouller B; Miller JH; Majumdar S; Kivell BM
    Neuropharmacology; 2021 Mar; 185():108445. PubMed ID: 33383089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphine can produce analgesia via spinal kappa opioid receptors in the absence of mu opioid receptors.
    Yamada H; Shimoyama N; Sora I; Uhl GR; Fukuda Y; Moriya H; Shimoyama M
    Brain Res; 2006 Apr; 1083(1):61-9. PubMed ID: 16530171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and characterization of a dual kappa-delta opioid receptor agonist analgesic blocking cocaine reward behavior.
    Váradi A; Marrone GF; Eans SO; Ganno ML; Subrath JJ; Le Rouzic V; Hunkele A; Pasternak GW; McLaughlin JP; Majumdar S
    ACS Chem Neurosci; 2015 Nov; 6(11):1813-24. PubMed ID: 26325040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BU74, a complex oripavine derivative with potent kappa opioid receptor agonism and delayed opioid antagonism.
    Husbands SM; Neilan CL; Broadbear J; Grundt P; Breeden S; Aceto MD; Woods JH; Lewis JW; Traynor JR
    Eur J Pharmacol; 2005 Feb; 509(2-3):117-25. PubMed ID: 15733546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of Selective and Mixed-Action Kappa and Delta Opioid Receptor Agonists on Pain-Related Behavioral Depression in Mice.
    Negus SS; St Onge CM; Lee YK; Li M; Rice KC; Zhang Y
    Molecules; 2024 Jul; 29(14):. PubMed ID: 39064909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice.
    Ide S; Minami M; Satoh M; Uhl GR; Sora I; Ikeda K
    Neuropsychopharmacology; 2004 Sep; 29(9):1656-63. PubMed ID: 15100703
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of the delta-opioid receptor is partially reduced, whereas activity of the kappa-receptor is maintained in mice lacking the mu-receptor.
    Matthes HW; Smadja C; Valverde O; Vonesch JL; Foutz AS; Boudinot E; Denavit-Saubié M; Severini C; Negri L; Roques BP; Maldonado R; Kieffer BL
    J Neurosci; 1998 Sep; 18(18):7285-95. PubMed ID: 9736649
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antinociceptive effects of two deltorphins analogs in the tail-immersion test in rats.
    Kotlinska JH; Gibula-Bruzda E; Witkowska E; Chung NN; Schiller PW; Izdebski J
    Peptides; 2013 Jan; 39():103-10. PubMed ID: 23183627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of kappa- and delta-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice.
    Reeta Kh; Mediratta PK; Rathi N; Jain H; Chugh C; Sharma KK
    Regul Pept; 2006 Jul; 135(1-2):85-90. PubMed ID: 16712978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
    Wang YJ; Tao YM; Li FY; Wang YH; Xu XJ; Chen J; Cao YL; Chi ZQ; Neumeyer JL; Zhang A; Liu JG
    J Pharmacol Exp Ther; 2009 Apr; 329(1):306-13. PubMed ID: 19136637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo.
    Wang Y; Tang K; Inan S; Siebert D; Holzgrabe U; Lee DY; Huang P; Li JG; Cowan A; Liu-Chen LY
    J Pharmacol Exp Ther; 2005 Jan; 312(1):220-30. PubMed ID: 15383632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist.
    Neilan CL; Husbands SM; Breeden S; Ko MC; Aceto MD; Lewis JW; Woods JH; Traynor JR
    Eur J Pharmacol; 2004 Sep; 499(1-2):107-16. PubMed ID: 15363957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.
    Brissett DI; Whistler JL; van Rijn RM
    Eur J Pain; 2012 Mar; 16(3):327-37. PubMed ID: 22337177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation.
    Pasquinucci L; Turnaturi R; Montenegro L; Caraci F; Chiechio S; Parenti C
    Eur J Pharmacol; 2019 Mar; 847():97-102. PubMed ID: 30690004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.
    Podolsky AT; Sandweiss A; Hu J; Bilsky EJ; Cain JP; Kumirov VK; Lee YS; Hruby VJ; Vardanyan RS; Vanderah TW
    Life Sci; 2013 Dec; 93(25-26):1010-6. PubMed ID: 24084045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.